Related Experiment Video
Updated: Feb 22, 2026
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
6.0K
Anticoagulation after coronary stenting: a systemic review.
1Department of Cardiology, China-Japan Friendship Hospital, No. 2 Yinghua Dongjie, Beijing 100029, China.
British Medical Bulletin
|September 16, 2017
Summary
Optimizing anticoagulant therapy after stenting is crucial for preventing thromboembolism. Research is ongoing to clarify risks and benefits of different anticoagulant agents and durations for improved patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Anticoagulant therapy is vital for preventing coronary and systemic thromboembolism post-stenting.
- Optimized anticoagulant regimens are actively researched for post-percutaneous coronary intervention (PCI) and long-term management.
Purpose of the Study:
- To review current literature on anticoagulant therapy after stenting.
- To identify areas of agreement, controversy, and future research directions in anticoagulant selection and duration.
Main Methods:
- Literature review of recent publications, including international guidelines and reviews.
- Analysis of evidence regarding anticoagulant efficacy and safety in patients undergoing stenting.
Main Results:
- Anticoagulant therapy improves prognosis by reducing thromboembolic events post-stenting.
- Uncertainty exists regarding the benefit-risk of parenteral anticoagulation for stent thrombosis and the role of bivalirudin.
- Emphasis is placed on long-term oral anticoagulation for systemic thromboembolism prevention.
Conclusions:
- Further research is needed to determine optimal anticoagulant strategies, balancing bleeding and ischemic risks.
- Large-scale trials are required to fully evaluate the safety and efficacy of agents like bivalirudin.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
397
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
397
01:28Acute Coronary Syndrome IV: Interprofessional Care
321
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
321
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
01:27Coronary Artery Disease V: Interprofessional Care
321
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
321
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K